Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

Université de Montréal

$150,000.00

Characterizing the molecular basis of ligand-biased signaling at beta-adrenergic G protein-coupled receptors

FY 2008-09

Summary
G protein-coupled receptors (GPCRs) represent the largest class of cell-surface receptors and are the target of nearly 40% of prescription drugs, including treatments for hypertension, migraine and heart failure. Drugs targeting these receptors were traditionally classified by their ability to promote receptor coupling to intracellular G proteins to initiate cellular signaling events. Recently it was shown that GPCRs are capable of eliciting signaling that is G protein-independent and may have important clinical consequences. Interestingly, the effects of drugs toward classical G protein-dependent pathways were not always conserved with respect to these newly discovered modes of signaling. For example, some drugs which block G protein-dependent signaling have been found to be activators of other pathways. It is hypothesized that drugs are capable of promoting unique structures of a given receptor, which differ in their ability to interact with signaling molecules inside the cell. The proposed research will investigate the variety of cellular events elicited from the β-adrenergic receptors (betaARs), which are the targets of drugs used to treat various cardiac disorders. Experiments will be performed to determine the signaling molecules necessary to mediate the repertoire of signaling events and how these important molecules differ in their interaction with unique receptor structures promoted by a panel of beta-adrenergic drugs. By increasing our understanding of the full repertoire of betaAR-mediated signaling events, novel pharmacological strategies may be revealed for the treatment of cardiac pathologies. In addition, correlating differences in the chemical structure of betaAR drugs with their functional effects would provide valuable information for the development of drugs capable of tighter regulation of cellular activity and greater clinical predictability.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
184604
Name
Stallaert Wayne
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Characterizing the molecular basis of ligand-biased signaling at beta-adrenergic G protein-coupled receptors
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Beta-Adrenergic Receptors; Bioluminescence Resonance Energy Transfer; Drug Efficacy; Drug Potency; G Protein-Coupled Receptors; Ligand-Biased Signaling; Mitogen-Activated Protein Kinase
Abstract
G protein-coupled receptors (GPCRs) represent the largest class of cell-surface receptors and are the target of nearly 40% of prescription drugs, including treatments for hypertension, migraine and heart failure. Drugs targeting these receptors were traditionally classified by their ability to promote receptor coupling to intracellular G proteins to initiate cellular signaling events. Recently it was shown that GPCRs are capable of eliciting signaling that is G protein-independent and may have important clinical consequences. Interestingly, the effects of drugs toward classical G protein-dependent pathways were not always conserved with respect to these newly discovered modes of signaling. For example, some drugs which block G protein-dependent signaling have been found to be activators of other pathways. It is hypothesized that drugs are capable of promoting unique structures of a given receptor, which differ in their ability to interact with signaling molecules inside the cell. The proposed research will investigate the variety of cellular events elicited from the β-adrenergic receptors (betaARs), which are the targets of drugs used to treat various cardiac disorders. Experiments will be performed to determine the signaling molecules necessary to mediate the repertoire of signaling events and how these important molecules differ in their interaction with unique receptor structures promoted by a panel of beta-adrenergic drugs. By increasing our understanding of the full repertoire of betaAR-mediated signaling events, novel pharmacological strategies may be revealed for the treatment of cardiac pathologies. In addition, correlating differences in the chemical structure of betaAR drugs with their functional effects would provide valuable information for the development of drugs capable of tighter regulation of cellular activity and greater clinical predictability.
Competitiondate
200811
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Stallaert, Wayne
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Université de Montréal - $150,000 Grant (2008-09) | Canada Spends